Zydus Cadila has received the final approval from the USFDA to market Diclofenac Sodium Topical Solution, 1.5 percent w/w. It is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). It will be manufactured at the group’s topical manufacturing facility at Ahmedabad. The group now has more than 185 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04. – Medical Buyer Bureau

10 Diagnostic Imaging Trends for 2018



Digital version